论文部分内容阅读
目的 研究拉西地平治疗原发性高血压的临床疗效和安全性。方法 ６０ 例原发性高血压患者随机分为两组：拉西地平组 ３２ 例（男 ２１，女 １１），年龄（５１．９±９．５）岁，每日予拉西地平（口服）２～６ ｍ ｇ；尼群地平组 ２８ 例（男 １８，女 １０），年龄（５０．６±９．８）岁，每日予尼群地平（口服）１０～２０ ｍ ｇ。疗程均为 ４ 周。结果 拉西地平组降压临床显效率 ７１．８％ ，有效率 ２１．９％ ，临床总有效率 ９３．７％ 。尼群地平组显效率 ６４．３％ ，有效率 ２１．４％ ，总有效率 ８５．７％ ，经 Ｋｉｄｉｔ检验 Ｐ ＞ ０．０５，无统计学差异。两组不良反应轻微。结论 拉西地平是治疗原发性高血压有效安全和使用方便的药物，值得临床推广应用。
Objective To study the clinical efficacy and safety of lacidipine in treating essential hypertension. Methods Sixty patients with essential hypertension were randomly divided into two groups: lacidipine group (male 21, female 11), age (51.9 ± 9.5) years, and daily lacidipine (oral) 2 to 6 m g; nitrendipine group 28 (male 18, female 10), age (50.6 ± 9.8) years old, daily to nitrendipine (oral) 10 ~ 20 m g. The course of treatment is 4 weeks. Results The clinical effective rate of lacidipine was 71.8%, the effective rate was 21.9%, and the total clinical effective rate was 93.7%. Nitrendipine group was 64.3% efficient, effective rate of 21.4%, the total efficiency of 85.7%, Kidney test P> 0.05, no significant difference. Two groups of minor adverse reactions. Conclusion Laceidipine is an effective, safe and convenient drug for the treatment of essential hypertension, which is worthy of clinical application.